Open AccessMDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients
Author(s) -
Milesi,
Vanni Borghi,
Marcello Pinti,
Cristian Bellodi,
Enrico Lugli,
Stefania Maffei,
Leonarda Troiano,
Luca Richeldi,
Cristina Mussini,
Roberto Esposito,
Andrea Cossarizza
Publication year - 2003
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200307250-00016
Subject(s) - genotype , antiretroviral drug , slco1b1 , antiretroviral therapy , immunology , p glycoprotein , drug , human immunodeficiency virus (hiv) , glycoprotein , drug naïve , biology , virology , medicine , viral load , pharmacogenetics , pharmacology , gene , drug resistance , genetics , multiple drug resistance
P-glycoprotein, a membrane-localized protein transporter, codified by the MDR1 gene, influences the response to pharmacological treatments, including antiretroviral drugs. MDR1 polymorphism C3435T is correlated with the functionality of the protein. We investigated the influence of this polymorphism in the reconstitution of the peripheral CD4 T cell pool in 149 drug-naive HIV-positive patients starting highly active antiretroviral therapy. The MDR1 C3435Tpolymorphism did not influence response to therapy, suggesting no disadvantages for individuals with a different genotype.